🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

43 results for “X4” Clear

  1. BCX4430

    Biocryst

    Filovirus Infections

    phase 1 small molecule completed

    1 trial

  2. INBRX-105 - PDL1x41BB antibody

    Inhibrx Biosciences

    Metastatic Solid Tumors

    phase 1 small molecule terminated

    1 trial

  3. IRX4204

    IO Biotech

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  4. IRX4204

    IO Biotech

    Lung Cancer, Nonsmall Cell

    phase 1 small molecule terminated

    1 trial

  5. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  6. LX4211

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  7. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  8. LX4211 400 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  9. LX4211 800 mg

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  10. Mavorixafor

    X4 Pharmaceuticals, Inc

    Hepatic Insufficiency

    phase 1 small molecule active

    1 trial

  11. Mavorixafor

    X4 Pharmaceuticals, Inc

    Waldenstrom's Macroglobulinemia

    phase 1 small molecule completed

    1 trial

  12. Mavorixafor

    X4 Pharmaceuticals, Inc

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  13. ORX489 Tablets

    Centessa Pharmaceuticals plc

    Healthy Adult Male and Female Volunteers

    phase 1 small molecule active

    1 trial

  14. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  15. X4P-001

    X4 Pharmaceuticals, Inc

    Melanoma

    phase 1 small molecule completed

    1 trial

  16. X4P-001

    X4 Pharmaceuticals, Inc

    Healthy

    phase 1 small molecule terminated

    1 trial

  17. [14C]-LX4211

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  18. Cytokine-induced killer cells+ FOLFOX4

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    approved small molecule completed

    1 trial

  19. Pariglasgene brecaparvovec

    Lacuna Pharma Pty Ltd

    Glycogen storage disease type Ia (GSDIa)

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources